CurrentHealth NetPolicy CP PMN.04

Clinical Policy: Non-Calcium Phosphate Binders

Authorization and medical necessity criteria for non-calcium phosphate binders for treatment of hyperphosphatemia in patients with chronic kidney disease or ESRD, and for ferric citrate (Auryxia) when used for iron deficiency anemia in CKD not on dialysis. Applies to Commercial, HIM, and Medicaid lines of business.

Policy Summary

PayerHealth Net

PolicyClinical Policy: Non-Calcium Phosphate Binders

Policy CodePolicy CP PMN.04

Change TypeNo material changes noted

Effective DateNov 15, 2017

Next Review DateN/A

Key ActionSubmit office notes, lab results, or other clinical documentation showing member meets all approval criteria when requesting prior authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5drugs requiring auth

12 monthsstandard approval duration

4-week trialrequired trial duration

≤2520 mg/dayAuryxia max iron

Coverage and Medical Necessity Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Approval Criteria for Hyperphosphatemia

Covered when ALL of the following are met

root: Initial approval for non-calcium phosphate binders (Auryxia, Fosrenol, Renvela, Renagel, Velphoro, lanthanum)

diagnosis: Diagnosis of hyperphosphatemia associated with chronic kidney disease (CKD) or end-stage renal disease (ESRD)

chunk 4

prescriber_or_dialysis: Prescribed by or in consultation with a nephrologist, OR member is on dialysis

chunk 4

age_agent_specific: Agent-specific minimum ages apply: sevelamer carbonate (Renvela) ≥ 6 years; Velphoro ≥ 9 years; other agents per adult labeling unless specified

chunks 4,30

step_or_exception

step_failure_calcium_acetate: Failure of a 4-week trial of calcium acetate at up to maximally indicated doses (e.g., persistent serum phosphorus ≥5.5 mg/dL), unless contraindicated or intolerant4 weeks
chunk 4
hypercalcemia_exception: Hypercalcemia: corrected total serum calcium > 10.2 mg/dL within the previous 30 days> 10.2 mg/dL
chunk 6
vascular_calcifications_exception: History of severe vascular and/or soft-tissue calcifications
chunk 6

additional_agent_steps: Agent-specific additional step requirements where applicable: for Auryxia or Renagel, failure of a 4-week trial of Fosrenol (generic preferred) or Renvela (generic preferred) at maximally indicated doses may be required unless contraindicated; for Velphoro, similar generic-preferred step trials are required for adults unless contraindicated4 weeks

chunk 6

generic_preference: Member must use generic formulations when available for Fosrenol (lanthanum), Renvela (sevelamer carbonate), Renagel (sevelamer hydrochloride), and Auryxia (ferric citrate) unless contraindicated or clinically significant adverse effects occur

chunks 7,13,14

dose_limits: Requested dose must not exceed agent-specific maximum daily limits (Auryxia ferric iron ≤ 2,520 mg/day; lanthanum (Fosrenol) ≤ 4,500 mg/day; Renvela ≤ 14 g/day; Renagel ≤ 13 g/day; Velphoro ≤ 3,000 mg/day)see agent-specific limits

chunk 7

pa_may_be_required: Prior authorization may be required for Fosrenol and Renvela per policy operational notes

chunk 6

Auryxia (Ferric citrate) for Iron Deficiency Anemia in CKD not on dialysis

Covered when ALL of the following are met

root: Auryxia (ferric citrate) for iron deficiency anemia in CKD not on dialysis

agent_request: Request is for ferric citrate (Auryxia)

chunk 9

indication: Diagnosis of iron deficiency anemia in a patient with chronic kidney disease

chunk 9

not_on_dialysis: Member is not on dialysis

chunk 10

trial_of_oral_iron: Failure of a 4-week adherent trial of alternative oral iron therapy (e.g., ferrous sulfate, ferrous fumarate, ferrous gluconate) unless contraindicated or clinically significant adverse effects are experienced4 weeks

chunk 10

generic_preference: Member must use generic ferric citrate when available unless contraindicated or clinically significant adverse effects are experienced

chunks 10,14

dose_limit: Dose does not exceed 2,520 mg ferric iron (12 tablets) per day≤2520 mg/day

chunks 7,11

Continuation (Renewal) Criteria

Covered when ALL of the following are met

continuity_of_care: Member is currently receiving the medication and enrolled in a state/product with continuity of care regulations, OR member previously met initial approval criteria

chunk 13

clinical_response: Member is responding positively to therapy (examples: reduction in serum phosphorus from pretreatment level; maintenance of serum phosphorus < 5.5 mg/dL; increased hemoglobin for Auryxia)< 5.5 mg/dL for phosphorus as maintenance goal

chunk 13

generic_and_dose_limits: Continue requiring use of generic when available and dosing does not exceed agent-specific maximumssee product maximums

chunks 13,14

Initial and maintenance therapy

Covered when prescribed for hyperphosphatemia or indicated iron deficiency anemia with monitoring and dose titration per product labeling.

product_specific_dosing_and_monitoring: Prescribed for an approved indication (hyperphosphatemia or iron deficiency anemia where indicated) AND dosing and titration follow product-specific guidance: examples include Auryxia 1 tablet PO TID for iron deficiency anemia (adjust to hemoglobin goal) and Auryxia 2 tablets PO TID titrated by serum phosphorus for phosphatemia; Fosrenol titrated to a maximum of 4,500 mg/day; Renvela starting doses and titration based on serum phosphorus (>5.5 to <7.5 mg/dL = 0.8 g PO TID; ≥7.5 mg/dL = 1.6 g PO TID) and max 14 g/day; Renagel max 13 g/day; Velphoro starting 500 mg PO TID with meals and max 3,000 mg/day; titrate per product labeling.see product maximums

chunks 23,19

Non–FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety consistent with the applicable off‑label use policy or evidence of coverage. Refer to the off‑label use policies for the relevant line of business: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), and CP.PMN.53 (Medicaid), or to the plan's evidence of coverage documents for adjudication of requests outside this policy.

Several agent‑specific contraindications are noted. Auryxia (ferric citrate) is contraindicated in patients with iron overload syndromes (e.g., hemochromatosis). Fosrenol (lanthanum carbonate) is contraindicated in patients with bowel obstruction, ileus, or fecal impaction and in those with hypersensitivity to Fosrenol or any ingredient. Renvela (sevelamer carbonate) and Renagel (sevelamer hydrochloride) are contraindicated in patients with bowel obstruction or known hypersensitivity to the product or excipients. Velphoro has no contraindications reported in the appendix.

If the requested use is not listed in this policy, follow the referenced formulary/no‑coverage or non‑formulary policies for the member's line of business. For formulary products or PDL items, consult the applicable no‑coverage criteria policy (e.g., CP.CPA.190 for Commercial, HIM.PA.33 for Health Insurance Marketplace, CP.PMN.255 for Medicaid). For non‑formulary requests, refer to the non‑formulary policies (e.g., CP.CPA.190, HIM.PA.103, or CP.PMN.16). If the use is not specifically addressed and criterion 1 above does not apply, refer to the off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), and CP.PMN.53 (Medicaid).

Coding and Code References

HCPCS codes referencedHCPCS

J0601	HCPCS code added to policy (specific description not provided in source).
J0602	Sevelamer carbonate (Renvela or therapeutically equivalent), oral, powder; 20 mg for ESRD on dialysis.
J0603	Sevelamer hydrochloride (Renagel or therapeutically equivalent), oral, 20 mg for ESRD on dialysis.
J0605	HCPCS code added to policy (specific description not provided in source).
J0607	Lanthanum carbonate, oral, 5 mg for ESRD on dialysis.
J0608	HCPCS code added to policy (specific description not provided in source).
J0609	HCPCS code added to policy (specific description not provided in source).

Serum phosphorus — dosing and titration thresholds

Renvela starting doses by serum phosphorusAdults on dialysis: if serum phosphorus >5.5 to <7.5 mg/dL → 0.8 g PO TID with meals; if ≥7.5 mg/dL → 1.6 g PO TID with meals

Renvela pediatric starting dose (≥6 years)Based on body surface area: BSA 0.75 to <1.2 m2 → 0.8 g PO TID with meals; BSA ≥1.2 m2 → 1.6 g PO TID with meals

Auryxia titration for phosphatemiaAuryxia: 2 tablets PO TID with meals; titrate by 1 tablet per dosing interval based on serum phosphorus

Fosrenol dosing and titrationLanthanum (Fosrenol): start 1,500 mg PO daily in divided doses; titrate by 750 mg/day every 2–3 weeks based on serum phosphorus; max 4,500 mg/day

Agent maximum dose examplesExamples: Renvela max 14 g/day; Renagel max 13 g/day; Velphoro typical start 500 mg PO TID with meals; Auryxia max 12 tablets/day

Provider Requirements, Prior Authorization, and Billing

Prior Authorization

Prior Authorization / HCPCS

Prior Authorization Required — Auryxia, Fosrenol, Renvela, Renagel, and Velphoro may require prior authorization. Providers should obtain PA before initiating therapy through the medical benefit for non-formulary or specialty requests. HCPCS J-codes may apply for ESRD on dialysis billing; see coding guidance.

Affected drugs: Auryxia (ferric citrate), Fosrenol (lanthanum carbonate), Renvela (sevelamer carbonate), Renagel (sevelamer hydrochloride), Velphoro (sucroferric oxyhydroxide)
HCPCS: J0601, J0602, J0603, J0605, J0607, J0608, J0609 may be referenced for dialysis-related billing

Step Therapy

Step Therapy / Trial Requirements

Step therapy: a 4-week trial of calcium acetate at maximally indicated doses is generally required before approval of non-calcium phosphate binders, unless contraindicated or clinically significant adverse effects occur. For certain agents (e.g., Auryxia or Renagel) a trial of Fosrenol or Renvela (generic preferred) may be required prior to approval. Illinois HIM requests: step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.

Typical failure threshold: serum phosphorus ≥ 5.5 mg/dL after a 4-week trial
Agent-specific notes: Fosrenol — use generic lanthanum carbonate unless contraindicated

Documentation Required

Documentation Requirement

Documentation Requirement — Providers must submit supporting clinical documentation with PA requests. Failure to provide required documentation may result in denial.

Required documentation: office chart notes, recent lab results (including serum phosphorus, corrected calcium, PTH when relevant), dialysis status, and consultation notes if applicable
Timing: recent corrected total serum calcium within 30 days when citing hypercalcemia

Documentation Required

Supporting Documentation

Supporting documentation should demonstrate that all clinical criteria are met: diagnosis of hyperphosphatemia associated with CKD/ESRD, prescriber specialty (nephrologist or consult), age requirements per agent, prior trials and reasons for failure or contraindication, and relevant laboratory values (serum phosphorus, corrected calcium, PTH).

Diagnosis and indication: CKD/ESRD-related hyperphosphatemia
Prior therapy: dates, doses and outcomes for calcium acetate, Fosrenol, Renvela or other preferred alternatives
Lab values: serum phosphorus, corrected total serum calcium, PTH (two measurements within 180 days if required)
Dialysis status and prescriber consultation documentation

Billing Rule

Claims Documentation

Claims Documentation & Coding — When submitting claims, reference current professional coding guidance and include appropriate documentation to support medical necessity. Use the HCPCS codes where applicable for ESRD on dialysis; inclusion of codes in this policy is informational only and does not guarantee coverage.

Providers should reference up-to-date coding sources prior to claim submission
Include supporting clinical documentation with the claim to substantiate PA and medical necessity

Denial Risk

Coding-related Denial Risk

Coding-related Denial Risk — Incorrect, incomplete, or non-covered codes and missing linkage between submitted codes and clinical documentation can lead to denial or delayed payment.

Common risk areas: wrong HCPCS code selection for dialysis medications, omission of required documentation tying the J-code claim to PA approval, or billing an outpatient drug under pharmacy benefit when medical benefit PA is required
Codes referenced (informational): J0601, J0602, J0603, J0605, J0607, J0608, J0609

Note

Therapeutic Alternatives / Switching Guidance

Therapeutic Alternatives / Switching Guidance — Where step therapy requires use of calcium acetate or preferred generics first, dosing conversion and switching guidance is provided (e.g., calcium acetate to Renvela starting doses). For Fosrenol, generic lanthanum carbonate is preferred unless contraindicated. Consider agent-specific age and indication constraints when switching.

Switching note: dosing conversions from calcium acetate to Renvela are provided in dosing appendix (use clinical dosing table)
Fosrenol: require generic lanthanum carbonate use unless contraindicated
Consider age-based eligibility: Renvela ≥ 6 years (pediatrics dosing by BSA), Velphoro ≥ 9 years

Background and Rationale

Hyperphosphatemia commonly occurs in patients with chronic kidney disease (CKD) and end‑stage renal disease (ESRD) due to impaired renal phosphate excretion and disturbances in mineral metabolism. Elevated serum phosphorus contributes to secondary hyperparathyroidism and increases the risk of vascular and soft‑tissue calcification. Non‑calcium phosphate binders (for example, sevelamer formulations, lanthanum carbonate, ferric citrate, and sucroferric oxyhydroxide) are used to control serum phosphorus in patients on dialysis and are often preferred when hypercalcemia or vascular calcification is present. Additionally, ferric citrate (Auryxia) has an approved role in treating iron‑deficiency anemia in adults with CKD not on dialysis, providing both phosphate binding and iron replacement in that setting.

Definitions and Abbreviations

CKD — definition

TermCKD — chronic kidney disease

ContextListed in Appendix A: Abbreviation/Acronym Key

Clinical relevanceCKD is the primary condition associated with hyperphosphatemia for which non-calcium phosphate binders are authorized

ESRD — definition

TermESRD — end-stage renal disease

ContextDefined in Appendix A: Abbreviation/Acronym Key

Clinical relevanceESRD patients on dialysis are a target population for phosphate binder therapy per policy criteria

PTH — definition

TermPTH — parathyroid hormone

ContextListed in Appendix A: Abbreviation/Acronym Key

Clinical relevancePTH is a referenced laboratory/clinical parameter in management of mineral bone disorder in CKD/ESRD

CKD / ESRD — abbreviations (Appendix A)

Abbreviations notedCKD: chronic kidney disease; ESRD: end-stage renal disease

LocationAppendix A: Abbreviation/Acronym Key

Policy useAbbreviations used throughout policy for diagnosis and criteria definitions

Contraindications (examples)

Auryxia (ferric citrate)Contraindication example: iron overload syndromes (e.g., hemochromatosis)

Fosrenol (lanthanum)Contraindication examples: bowel obstruction, ileus, fecal impaction; hypersensitivity to Fosrenol or any ingredient

Renvela (sevelamer carbonate) / Renagel (sevelamer hydrochloride)Contraindication examples: bowel obstruction; known hypersensitivity to sevelamer or excipients

Velphoro (sucroferric oxyhydroxide)Reported as none reported in Appendix C